Abstract Number: 1711 • 2018 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
Background/Purpose: Measurement of treatment response in SLE clinical trials has been based on measurement of change from baseline; however a treat-to-target analysis has seldom been…Abstract Number: 1840 • 2017 ACR/ARHP Annual Meeting
Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial
Background/Purpose: Remission in SLE is a desirable target, however there is no gold standard for the definition of remission. An international task force agreed on…Abstract Number: 2923 • 2017 ACR/ARHP Annual Meeting
A Propensity Score-Matched Study of Organ Damage in Patients with Systemic Lupus Erythematosus from the BLISS Long-Term Extension Trials Versus the Toronto Lupus Cohort: A Post Hoc Longitudinal Analysis
Background/Purpose: Two Phase 3, randomized controlled trials (BLISS 52/76) studied the efficacy and safety of belimumab plus standard of care (SoC) in systemic lupus erythematosus…Abstract Number: 1585 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials
Background/Purpose: Patients with systemic lupus erythematosus (SLE) frequently receive corticosteroids (CS) as standard therapy. We examined the effects of belimumab on CS dose across 52…Abstract Number: 1837 • ACR Convergence 2020
Clinical Outcomes in Lupus Nephritis by Renal Response Status: A Retrospective Analysis of the Hopkins Lupus Cohort
Background/Purpose: A retrospective analysis of the Hopkins Lupus Cohort (a prospective, longitudinal study of patients [pts] with systemic lupus erythematosus) reported that renal response (complete/partial/none)…Abstract Number: 1948 • ACR Convergence 2020
Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes
Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…Abstract Number: 2525 • 2019 ACR/ARP Annual Meeting
Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus
Background/Purpose: SLE is a chronic autoimmune disease characterized by diverse clinical manifestations and flares associated with organ damage, resulting in substantial short-term management costs. Results…Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…Abstract Number: 2572 • 2019 ACR/ARP Annual Meeting
Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status
Background/Purpose: Belimumab (BEL) is a B-lymphocyte stimulator (BLyS) inhibitor approved as an add-on to standard of care (SoC) for patients with autoantibody-positive SLE with active…Abstract Number: 2864 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Background/Purpose: Belimumab (BEL) is the first treatment approved for children with systemic lupus erythematosus (SLE) from 5 years of age and older.1 This approval was…Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…Abstract Number: 2627 • 2018 ACR/ARHP Annual Meeting
Not All Clinical Responders in SLE Are Equal: Comparison of Subcutaneous Belimumab + Standard of Care Responders to Placebo + Standard of Care Responders
Background/Purpose: To determine whether degree of response among responders to subcutaneous (SC) belimumab (BEL) + standard of care (SoC) is greater than that for responders…Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…Abstract Number: 1839 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials
Background/Purpose: Randomized controlled trials (RCTs) of new SLE treatments are hampered by the lack of effective outcome measures that are responsive to change and clinically…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »